基本信息
浏览量:0
职业迁徙
个人简介
Clinical Specialties: Internal Medicine,
Research Areas: Chimeric Antigen Receptor T cells, Chimeric Auto-Antigen Receptor T cells, Adoptive Cell Therapies, Listeria based vaccines, Canine hematopoietic cancers, Canine osteosarcoma, Canine Urothelial Carcinoma, Canine Soft Tissue Sarcomas
Our translational research program focuses on a comparative approach, utilizing immunologically intact, canine patients with spontaneous cancer.
This comparative approach provides a unique opportunity to evaluate the safety and effectiveness of next generation immunotherapies in a parallel canine patient population that presents the same challenges to effective immunotherapy as seen in human patients.
The aim of this approach is to accelerate the translation of the most promising pre-clinical discoveries into the human clinic. Our lab is actively involved in developing the canine “model” for evaluating CART cell therapies.
We have successfully translated several promising strategies to generate anti-tumor immunity from the lab and pre-clinical murine models into client owned dogs suffering from lymphoma, osteosarcoma and hemangiosarcoma.
Our lab evaluates the immunological consequences of immune–based therapies in client owned dogs using flow cytometric phenotyping and functional assays including cytokine production, cytotoxicity assays and ELISpot assays to investigate canine T cell responses.
Dr. Mason leads a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma. She also leads the coordinating center for Canine Cancer Immunotherapy Trials (U24) as part of the Cancer Moonshot program. The lab has extensive experience in methodology to robustly expand and genetically modify canine T cells ex vivo and is the first to perform clinical trials using CART cells in client owned dogs with treatment naïve or relapsed B-NHL. This single site trial is performed at the Veterinary Hospital of the University of Pennsylvania.
Research Areas: Chimeric Antigen Receptor T cells, Chimeric Auto-Antigen Receptor T cells, Adoptive Cell Therapies, Listeria based vaccines, Canine hematopoietic cancers, Canine osteosarcoma, Canine Urothelial Carcinoma, Canine Soft Tissue Sarcomas
Our translational research program focuses on a comparative approach, utilizing immunologically intact, canine patients with spontaneous cancer.
This comparative approach provides a unique opportunity to evaluate the safety and effectiveness of next generation immunotherapies in a parallel canine patient population that presents the same challenges to effective immunotherapy as seen in human patients.
The aim of this approach is to accelerate the translation of the most promising pre-clinical discoveries into the human clinic. Our lab is actively involved in developing the canine “model” for evaluating CART cell therapies.
We have successfully translated several promising strategies to generate anti-tumor immunity from the lab and pre-clinical murine models into client owned dogs suffering from lymphoma, osteosarcoma and hemangiosarcoma.
Our lab evaluates the immunological consequences of immune–based therapies in client owned dogs using flow cytometric phenotyping and functional assays including cytokine production, cytotoxicity assays and ELISpot assays to investigate canine T cell responses.
Dr. Mason leads a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma. She also leads the coordinating center for Canine Cancer Immunotherapy Trials (U24) as part of the Cancer Moonshot program. The lab has extensive experience in methodology to robustly expand and genetically modify canine T cells ex vivo and is the first to perform clinical trials using CART cells in client owned dogs with treatment naïve or relapsed B-NHL. This single site trial is performed at the Veterinary Hospital of the University of Pennsylvania.
研究兴趣
论文共 87 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cell reports. Medicineno. 10 (2023): 101241-101241
CANCER SCIENCE (2023): 69-69
引用0浏览0引用
0
0
Sho Yoshimoto,Nicholas Chester,Ailian Xiong,Enrico Radaelli, Hong Wang, Marc Brillantes,Gayathri Gulendran,Patrick Glassman,Don L. Siegel,Nicola J. Mason
mAbsno. 1 (2023): 2287250-2287250
BONE MARROW TRANSPLANTATIONno. SUPPL 1 (2022)
引用0浏览0引用
0
0
CANCER RESEARCHno. 12 (2022)
引用0浏览0引用
0
0
Cellular Oncologyno. 6 (2022): 1277-1295
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn